U.S.: Former GW Pharmaceuticals Advisor Discusses Future of Medical Cannabis
Cannabis business website Ganjapreneur has announced its latest podcast episode, which features prominent medical marijuana researcher Dr. Ethan Russo in a conversation about his research regarding the Endocannabinoid System — a unique system found in all vertebrates, including humans, which promotes homeostasis and a biological balance across bodily functions.
In the interview, Ganjapreneur podcast host Shango Los asks Dr. Russo about Endocannabinoid Deficiency (ECD) and the potential for it to be treated with cannabis. As Russo explains, ECD is just coming into general awareness now as a cause behind several conditions including Migraines, Fibromyalgia, Irritable Bowel Syndrome, Phantom Limb Pain, Infantile colic, Glaucoma, PTSD, Bipolar disease and others.
When used as a form of treatment, "A lot of what THC does is paralleled by the effects of... natural chemicals in the body that everyone has," Dr. Russo explained.
Before going public with his research, Dr. Russo worked for years as senior medical advisor for GW Pharmaceuticals; there, he oversaw three separate clinical trials for Sativex, one of the world's first cannabinoid-based medicines to be approved for public use.
Today, he is medical director at Phytecs, a company specializing in the production of cannabis-based treatments related to the endocannabinoid system. Due to legal complications and concerns over the federal legality of his work, Dr. Russo only began to speak publicly about his research earlier this year.